You are currently viewing Citation Abstract|Immunomodulatory hydrogel enhances treatment of glioblastoma

    Citation Abstract|Immunomodulatory hydrogel enhances treatment of glioblastoma

    On September 22, 2023, Professor Ran Wang, Professor Shilei Ni, and their colleagues from the Department of Neurosurgery and the Institute of Brain and Mind Inspired Science at Qilu Hospital, Shandong University, Jinan, Shandong, China, published the paper titled ‘Lymph node-inspired immunoregulatory hydrogel with siRNA delivery property for postoperative glioblastoma treatment’ online in the CHEMICAL ENGINEERING JOURNAL (IF=15.1).This paper utilized reagents from Multi Sciences (Hangzhou, China), including Anti-Mouse CD3ε, FITC (Clone:145-2C11) flow cytometry antibody (Catalog number: F2100301), Anti-Mouse CD80 (B7-1), FITC (Clone:16-10A1) flow cytometry antibody (Catalog number: F2108001), Anti-Mouse CD86 (B7-2), PE (Clone:GL-1) flow cytometry antibody (Catalog number: F2108602), Anti-Mouse CD4, APC (Clone:GK1.5) flow cytometry antibody, and Anti-Mouse CD8α (Clone:53-6.7), PE flow cytometry antibody (Catalog number: F2100403).

    (C, E, G ) Flow cytometry analysis of mature DCs, CD4+ T cells, CD8+ T cells and TEM.

    Glioblastoma (GBM) is a challenging malignant tumor in the central nervous system as many drugs struggle to penetrate the blood-brain barrier (BBB), making treatment difficult. The presence of meningeal lymphatics suggests significant potential for immunotherapy in treating GBM; however, limited immune cell numbers and the immunosuppressive tumor microenvironment pose additional challenges. Lymph nodes (LNs) play a crucial role in anti-tumor immunity by promoting cell interactions and lymphocyte proliferation. Inspired by LN function, an acid-responsive hydrogel was engineered to enhance local immune therapeutic effects. This hydrogel was locally injected into the tumor surgical cavity, bypassing the BBB, and targeted to knock down extracellular 5′-nucleotidase to reverse adenosine-induced immunosuppression in the tumor microenvironment using small interfering RNA (siRNA). This led to antigen release and the establishment of a local inflammatory microenvironment with imiquimod, promoting cell interactions and lymphocyte proliferation, significantly improving tumor clearance. This study proposes a novel GBM immunotherapy approach inspired by lymph node function and demonstrates promising clinical translational value for future treatments.

    Multi Sciences products support scientific research
    Product name Anti-Mouse CD3ε, FITC (Clone:145-2C11) Flow cytometry antibodies Catalog number;F2100301
    Zhao M, Li J, Chen F,et al. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation. J Control Release. 2023 Mar;355:211-227.
    Gao, Xiong et al. “Immunoregulatory activity of a low-molecular-weight heteropolysaccharide from Ganoderma leucocontextum fruiting bodies in vitro and in vivo.” Food Chemistry: X 14 (2022):
    Product name Anti-Mouse CD80 (B7-1), FITC (Clone:16-10A1)Flow cytometry antibodies Catalog number;F2108001
    Zhang C, Xu Z, Di H, et al. Gadolinium-doped Au@prussian blue nanoparticles as MR/SERS bimodal agents for dendritic cell activating and tracking. Theranostics. 2020 May 15;10(13):6061-6071.
    Xing R, Song X, Liu L,et al . Quaternized chitosan-coated liposomes enhance immune responses by co-delivery of antigens and resveratrol. Int J Pharm. 2022 Nov 25;628:122277.

    About Multi Sciences

    Multi Sciences was established in 2002. It is a high-tech enterprise engaged in biology and immunology-related diagnostic reagents R&D and production, including ELISA reagents, flow cytometry reagents, IVD products and etc.
    The production system is certified with ISO9001 international quality management system, the research and development system is certified with ISO13485 international quality management system.
    By the end of 2023, a total of 8820 SCI research papers cited Multi Sciences products, including top journals such as Science, Nature, and Cell, with the highest Impact Factor (IF) 68.164.
    Our products are sold in many countries around the world and are highly praised by research and corporate customers.

    Zide Wang, Huimin Geng, Yuqi Zhang,et al. Lymph node-inspired immunoregulatory hydrogel with siRNA delivery property for postoperative glioblastoma treatment,Chemical Engineering Journal,2023:146343.
    Original Article Link: